---
document_datetime: 2024-11-21 10:44:59
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/praxbind-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: praxbind-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 18.0211055
conversion_datetime: 2025-12-24 09:25:08.47658
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Praxbind

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0035              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 20/11/2024                          |                                             | SmPC and PL                      |           |
| IB/0033              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 10/07/2023                          | 25/01/2024                                  | SmPC                             |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0034/G   | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   | 07/07/2023   | n/a        |      |                                                                                                                                                                                                                                                     |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0032     | B.II.c.3.a.2 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or reagents USED in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product                                                                                                                                              | 08/06/2023   | n/a        |      |                                                                                                                                                                                                                                                     |
| IB/0031     | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                          | 25/04/2023   | n/a        |      |                                                                                                                                                                                                                                                     |
| IB/0029     | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                        | 18/01/2023   | 25/01/2024 | SmPC | Product information section 6.3 is updated to reflect the shelf-life extension of the finished product Praxbind 2.5 g/50 mL solution for injection/infusion (EU/1/15/1056/001) as packaged for sale from 3 years to 4 years when stored at 2 - 8Â°C. |
| IB/0030     | B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation                                                                                                                                                                                                                                                                                                         | 16/01/2023   | n/a        |      |                                                                                                                                                                                                                                                     |
| IB/0028/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                               | 22/09/2022   | n/a        |      |                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   |            |            |    |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10435 /202110 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                                                                                                                                                                                     | 10/06/2022 | n/a        |    | PRAC Recommendation - maintenance |
| IB/0026             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                         | 06/12/2021 | n/a        |    |                                   |
| IA/0025             | B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                                                                                                                                                                                                     | 08/10/2021 | n/a        |    |                                   |
| PSUSA/10435 /202010 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                                                                                                                                                                                     | 10/06/2021 | n/a        |    | PRAC Recommendation - maintenance |
| N/0024              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                               | 31/05/2021 | 29/09/2021 | PL |                                   |
| IA/0022             | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a                                                                                                                                                                                                                       | 08/01/2021 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Member State                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0021/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 07/01/2021 | 29/09/2021 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0020             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                            | 17/09/2020 | 29/09/2021 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0019              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                      | 28/05/2020 | 27/07/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the benefit-risk balance of Praxbind in its approved indication(s) (please refer to the Summary of Product Characteristics) remains favourable and therefore the renewal of the marketing authorisation is recommended, subject to the conditions as detailed in Annex II. The renewal is recommended to be granted with unlimited validity. |
| PSUSA/10435 /201910 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                                                                                                                                                   | 14/05/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0017/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                           | 16/03/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0016             | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/08/2019 | n/a |                                   |
| PSUSA/10435 /201810 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/05/2019 | n/a | PRAC Recommendation - maintenance |
| II/0014/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 04/04/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | the AS - Minor change in the manufacturing process of the AS B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol   |            |            |                           |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|-----------------------------------|
| PSUSA/10435 /201804 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                                                                                | 31/10/2018 | n/a        |                           | PRAC Recommendation - maintenance |
| IB/0012             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                            | 24/08/2018 | 02/08/2019 | SmPC and PL               |                                   |
| IB/0013             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                              | 16/08/2018 | n/a        |                           |                                   |
| PSUSA/10435 /201710 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                                                                                | 17/05/2018 | n/a        |                           | PRAC Recommendation - maintenance |
| II/0007             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                         | 09/11/2017 | 06/07/2018 | SmPC                      |                                   |
| PSUSA/10435 /201704 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                                                                                | 26/10/2017 | n/a        |                           | PRAC Recommendation - maintenance |
| IB/0008/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                        | 20/07/2017 | 06/07/2018 | SmPC, Annex II, Labelling |                                   |

<div style=\"page-break-after: always\"></div>

|                     | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data) B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product   |            |            | and PL   |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| PSUSA/10435 /201610 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                          | 05/05/2017 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0006             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                 | 03/04/2017 | 13/07/2017 | SmPC     |                                   |
| IB/0005             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                              | 23/03/2017 | n/a        |          |                                   |
| PSUSA/10435 /201604 | Periodic Safety Update EU Single assessment - idarucizumab                                                                                                                                                                                                          | 27/10/2016 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0003             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                 | 27/07/2016 | 13/07/2017 | SmPC     |                                   |
| IB/0002             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                              | 27/07/2016 | n/a        |          |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->